Back to search

Article

<em>KRAS/NRAS</em> Mutation-Associated Transcriptional Dysregulation Identifies <em>NRL</em>, <em>CREM </em>and <em>IL-6</em> as Candidate Prognostic Biomarkers in Multiple Myeloma

2026-07-23

Abstract excerpt

<h4>Background: </h4> Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy with variable responses to induction therapy that are not fully explained by current risk stratification systems. Mutations in RAS family genes are prevalent in MM, yet contemporary risk stratification systems do not include them despite their oncogenic potential. Our previous findings showed reduced tumor cell sensi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a828ae23-cabb-5846-87be-badab60752e5
DOI
10.20944/preprints202607.1712.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
<em>KRAS/NRAS</em> Mutation-Associated Transcriptional Dysregulation Identifies <em>NRL</em>, <em>CREM </em>and <em>IL-6</em> as Candidate Prognostic Biomarkers in Multiple MyelomaDOI 10.20944/preprints202607.1712.v1
Distinct Pathway Activities are Associated with Prognosis and Response to Bortezomib- containing Treatment in MCL1-M Based Molecular Subtypes of Multiple MyelomaSemantic proximity
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaSemantic proximity
Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.Semantic proximity
Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.Semantic proximity
Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Semantic proximity
Genome-Wide Identification of Potential Biomarkers in Multiple Myeloma Using Meta-Analysis of mRNA and miRNA Expression DataSemantic proximity
Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.Semantic proximity
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitionsSemantic proximity
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myelomaSemantic proximity
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaSemantic proximity
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)Semantic proximity
Select a neighboring publication to make it the new centre.